Previously, researchers reported that, in studies of NSCLC patients treated with PD-1 inhibitors, an increase in peripheral blood CD8+ T cells predicts a good treatment response, whereas an increase in the total T-cell count and the CD4+/CD8+ T-cell ratio is significantly associated with a poorer response (20). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.